JPH01305031A - Constitution-strengthening agent for prevention of cancer - Google Patents
Constitution-strengthening agent for prevention of cancerInfo
- Publication number
- JPH01305031A JPH01305031A JP63133705A JP13370588A JPH01305031A JP H01305031 A JPH01305031 A JP H01305031A JP 63133705 A JP63133705 A JP 63133705A JP 13370588 A JP13370588 A JP 13370588A JP H01305031 A JPH01305031 A JP H01305031A
- Authority
- JP
- Japan
- Prior art keywords
- magnesium hydroxide
- seawater
- cancer
- constitution
- concentrated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 51
- 201000011510 cancer Diseases 0.000 title claims abstract description 40
- 238000005728 strengthening Methods 0.000 title claims abstract description 20
- 230000002265 prevention Effects 0.000 title claims description 6
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims abstract description 42
- 239000000347 magnesium hydroxide Substances 0.000 claims abstract description 42
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims abstract description 42
- 239000013535 sea water Substances 0.000 claims abstract description 40
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 239000012452 mother liquor Substances 0.000 claims abstract description 25
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 12
- 239000011780 sodium chloride Substances 0.000 claims abstract description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims abstract description 5
- 239000003518 caustics Substances 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000012670 alkaline solution Substances 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 235000011116 calcium hydroxide Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000002075 main ingredient Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 20
- 235000008733 Citrus aurantifolia Nutrition 0.000 abstract description 6
- 235000011941 Tilia x europaea Nutrition 0.000 abstract description 6
- 239000004571 lime Substances 0.000 abstract description 6
- 239000008267 milk Substances 0.000 abstract description 5
- 210000004080 milk Anatomy 0.000 abstract description 5
- 235000013336 milk Nutrition 0.000 abstract description 5
- 239000000243 solution Substances 0.000 abstract description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 3
- 235000010755 mineral Nutrition 0.000 abstract description 3
- 239000011707 mineral Substances 0.000 abstract description 3
- 150000001639 boron compounds Chemical class 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract 1
- 229910052925 anhydrite Inorganic materials 0.000 abstract 1
- 239000012267 brine Substances 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 abstract 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 11
- 239000004576 sand Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 7
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 6
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229910052796 boron Inorganic materials 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 238000001914 filtration Methods 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- BELPJCDYWUCHKF-WAYWQWQTSA-N Methylazoxymethanol acetate Chemical compound CC(=O)OC\N=[N+](\C)[O-] BELPJCDYWUCHKF-WAYWQWQTSA-N 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000000292 calcium oxide Substances 0.000 description 3
- 235000012255 calcium oxide Nutrition 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000003200 Adenoma Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 206010007269 Carcinogenicity Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229910019440 Mg(OH) Inorganic materials 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010261 calcium sulphite Nutrition 0.000 description 2
- 231100000260 carcinogenicity Toxicity 0.000 description 2
- 230000007670 carcinogenicity Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BJNBRIBHKLJMAG-ARJAWSKDSA-N methylazoxymethanol Chemical compound C\[N+]([O-])=N\CO BJNBRIBHKLJMAG-ARJAWSKDSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 208000014680 small intestine neoplasm Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000001762 Gastric Dilatation Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229910003439 heavy metal oxide Inorganic materials 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000009019 intestinal benign neoplasm Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003071 polychlorinated biphenyls Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
Abstract
Description
【発明の詳細な説明】
本発明者は、60有余年にわたり各地の製塩地域に居住
したがその間入浜塩田(大酒塩田とは塩田地盤に砂を撒
き、開講の海水を地盤に浸透させ、毛細管現象により海
水を撒砂に補給させながら太陽熱及び風力により、水分
を蒸発させ、撒砂に塩分を晶析せしめ、その撒砂を沼井
と称する濾過装置に入れ海水にて付着した塩分を溶解し
て濃厚カン水分得る方式であって、砂は反覆して塩田に
撒く)における作業員(浜男、浜子、賽子、等と称する
)でガンに罹ったものを間がなかったのでこのことにつ
き研究を始めた。DETAILED DESCRIPTION OF THE INVENTION The present inventor has lived in various salt production areas for more than 60 years, and during that time he discovered Irihama Salt Fields (Osaka Salt Fields), a salt field where sand is sprinkled on the ground and seawater permeates into the ground. While replenishing the sand with seawater through capillary action, the water is evaporated using solar heat and wind power, salt is crystallized in the sand, and the sand is put into a filtration device called a numai, which dissolves the salt adhering to the seawater. A worker (known as Hamao, Hamako, Saiko, etc.) who worked on a method to obtain concentrated water in the salt pans (the sand was repeatedly scattered over the salt pans) was diagnosed with cancer, so research was conducted on this topic. started.
先ずこれを確認するため、兵庫県赤穂地域において、多
年大酒塩田を経営していた、赤穂西浜塩業組合における
大酒塩田(269ヘクタール)従業員の健康状層の追跡
調査を行ったところA表に示すような結果が得られた。First, in order to confirm this, we conducted a follow-up survey on the health status of the employees of the Osake Salt Farm (269 hectares) at the Ako Nishihama Salt Industry Association, which had been operating the Osake Salt Farm for many years in the Ako area of Hyogo Prefecture. The results shown in the table were obtained.
その結果、調査対象者は1885年から大酒塩田が廃止
された1959年までの74年間にわたっての追跡可能
であった従業員総人数2,015名(この時代、塩田従
事は世襲的であり、又追跡不可能な人は本人及び関係者
が当地に居住しておらず、所在が不明であった。)で、
その内退職時までの在職期間における、病、事故役者は
15名であったがガンに因る死亡者及び罹病者は皆無で
あった。詳細は表A2、表A3に記載のとおりである。As a result, the research subjects were a total of 2,015 employees who could be traced over the 74-year period from 1885 to 1959, when the Taizake Salt Farm was abolished. In addition, those who could not be traced did not live in the area and their whereabouts were unknown.)
Of these, 15 actors were sick or had accidents during their tenure up to the time of their retirement, but there were no deaths or illnesses due to cancer. Details are as described in Tables A2 and A3.
尚、退@後の健康追跡調査も可能な1432人について
行った。退職後、1年以内にガンに罹った者はなかった
が1961年より1976年3月現在までの間には、3
18名の死亡者があり、その内ガン死亡者はA表に記載
の如<42名を数えた。In addition, a post-retirement health follow-up survey was conducted on 1,432 people who were able to do so. No one contracted cancer within a year after retiring, but from 1961 to March 1976, 3.
There were 18 deaths, of which 42 people died from cancer as listed in Table A.
以上よりして大酒塩田作業員で現役でガンに罹ったもの
は皆無で又、退職後1年以内においてもガンに罹ったも
のはないということが判明した。Based on the above, it was found that none of the sake salt field workers had contracted cancer while on active duty, and none had contracted cancer within one year after retiring.
その後はガン罹患者が出現し、そのガンによる死亡率は
御飯社会におけるガン死亡率と大体同様であることも確
認された。After that, cancer patients appeared, and it was confirmed that the cancer mortality rate was roughly the same as the cancer mortality rate in the Japanese society.
塩田で作業する場合、多くは素足で行っているので脚足
部等よりの皮膚3通して何等かの物質が人体内に吸収さ
れるか空気中に飛散した微粉末として吸入されるかして
ガンの予防に役立っていたものと考えざるを得ない。そ
こで本発明者は人体に影響したであろう物質について研
究を行った。When working in salt fields, most of the work is done barefoot, so there is a possibility that some substances may be absorbed into the human body through the skin from the legs and feet, or inhaled as fine powder dispersed in the air. I can't help but think that it helped prevent cancer. Therefore, the present inventor conducted research on substances that may have affected the human body.
塩田の土壌、砂、海水の濃縮された母液、懸濁物質等、
あらゆる資料について専門機関と協同して種々調査した
がガンに対する有機性抗生物置は検出されなかった。依
って脚足部等の皮膚を通して塩田地盤や撒砂に含まれて
いる濃1?!母液中の成分が体内に吸収されている以外
にないと究明した。Salt farm soil, sand, concentrated mother liquor of seawater, suspended solids, etc.
Although we conducted various investigations on all materials in cooperation with specialized organizations, no organic antibiotics for cancer were detected. Therefore, is it possible that the concentration 1 is contained in the salt field ground and scattered sand through the skin of the legs and feet? ! It has been determined that the only reason for this is that the components in the mother liquor are absorbed into the body.
この母液は本発明の実施例に示す原料としての海水濃m
母液と略同様のものである。即ち、大酒塩田においては
海水中のNaC1、CaSO3の大部分は撒砂に晶析さ
れ、NaC1、Ca5O,以外の海水成分を含む母液は
濃厚溶液の状態で地盤及びは砂に付着している。従って
母液中には、海水中のホウ酸分、自然放射性核種物質そ
の他の微量成分、及びマグネシウム分が濃m含有されて
いる。母液中には例えばNa、Mg、Ca、S i、A
l、K 、Fe、Mn。This mother liquor is a concentrated seawater solution used as a raw material in the examples of the present invention.
It is almost the same as mother liquor. In other words, in the Taizake Salt Field, most of the NaCl and CaSO3 in the seawater are crystallized in the scattered sand, and the mother liquor, which contains seawater components other than NaCl, Ca5O, is attached to the ground and sand in the form of a concentrated solution. . Therefore, the mother liquor contains concentrated concentrations of boric acid, natural radionuclides and other trace components, and magnesium contained in seawater. The mother liquor contains, for example, Na, Mg, Ca, Si, A
l, K, Fe, Mn.
Sr、U、Se、Ra、Th、Rh、C1C4!、S等
が含まれその中の数種のものがガン予防に役立つもので
あるとの結論に到達した。Sr, U, Se, Ra, Th, Rh, C1C4! , S, etc., and it was concluded that several of them are useful for cancer prevention.
これ等の詳細に関しては下記に逐次説明する通りである
。These details will be explained in detail below.
海水中には陸上に存在する元素の大部分を溶存していて
約80種を数えその主なる成分の分析値の一例はB表の
通りである。この中には自然放射性核種、例えば2コ”
U + 22’ U + ” 2’ Ra 、 ”
’ S e 、 2コ2Th。Most of the elements present on land are dissolved in seawater, numbering about 80 types, and an example of the analysis values of the main components is shown in Table B. Among these are natural radionuclides, for example 2.
U + 22' U + "2'Ra,"
'S e, 2ko 2Th.
1γRl、 、 S OS、 、 l 4 C、4°に
等の物質が含まれていることは公知である。It is known that substances such as 1γRl, , SOS, , l4C, and 4° are contained.
大酒塩田の濃縮母液には当然この自然放射性物質が含有
されている。放射性物質はガンを誘引すると言われてい
るが極めて微量で自然界の前述の母液中に存在する適量
のものは逆にガンの発生を予防し、又これと相まってマ
グネ9911分、ホウ素分その他の微量成分も総合的に
ガン発生を予防しているものと考えられる。大酒塩田に
おいて作業する場合、海水成分が人体内に吸収されると
の説や、作業員に他の病気はあったがガンにはかからな
いということは本発明者のみでなく塩辛地帯において昔
から発言する者もあった。塩田fヤ業は極めて重労働で
あるので大食になりがちで胃拡張患者も比較的多かった
が、ガンに罹ったものは間かなかったのである。Naturally, the concentrated mother liquor from Taizake salt fields contains this naturally radioactive material. Radioactive substances are said to induce cancer, but in extremely small amounts, the appropriate amounts present in the aforementioned mother liquor in nature can actually prevent the development of cancer, and in conjunction with this, they can also cause small amounts of Magneto 9911, boron, and other substances. The ingredients are also thought to comprehensively prevent the development of cancer. The theory that seawater components are absorbed into the human body when working in the Taizake salt fields, and that the workers had other illnesses but not cancer, has been held not only by the inventor but also in the salty region for a long time. Some spoke out. Because Shioda's work was extremely hard work, he was prone to gluttony, and there were relatively many patients with gastric dilatation, but not many of them contracted cancer.
そこで本発明者は塩田で作業をしたと同じ(信用効果を
持ち込むことができればガンの罹病が予防できるのでは
ないかと考え、その手段として海水の濃縮母液中の微量
成分をこの母液中のマグネシウム分を利用して生成せし
めた水酸化マグネシウム中に吸着せしめたものを服用す
ることによって、同じ作用効果が人体内に採り入れられ
ると確信するに至った。Therefore, the present inventor thought that if we could bring in the same trust effect as we had done in the salt fields, we might be able to prevent cancer. He became convinced that the same effects could be introduced into the human body by taking a substance adsorbed in magnesium hydroxide produced using magnesium hydroxide.
そして自然放射性核種物質ホウ素化会物、ミネラル物質
等を海水中に存在する形で採り入れ、又マグオ・ジウム
分としては海水中のマグネシウム分をマグネシウム塩よ
り有効な水酸化マグネシウムとしてそれぞれ体内に採り
入れることに成功した。Then, natural radionuclide materials such as boron compounds, mineral substances, etc. are taken in the form that exists in seawater, and the magnesium content in seawater is taken into the body as magnesium hydroxide, which is more effective than magnesium salt. succeeded in.
すなわち本発明によれば、下記体質強化剤が提供される
:
(1)主成分として水酸化マグネシウムを含む海水微量
成分濃縮物からなるガン予防のための体質強化剤。That is, according to the present invention, the following constitution-strengthening agent is provided: (1) A constitution-strengthening agent for cancer prevention consisting of a seawater trace component concentrate containing magnesium hydroxide as a main component.
(2)海水微量成分濃縮物が、海水またはカン水から食
塩(N aC1)および硫酸カルシウム(CaSOl)
を取り除いてなる濃縮した母液に石灰乳または苛性アル
カリ溶液を加えて水酸化マグネシウムを生成せしめたも
のである第1項の体質強化剤。(2) Seawater trace component concentrates are salt (NaC1) and calcium sulfate (CaSOl) from seawater or canned water.
1. The constitution strengthening agent according to item 1, which is obtained by adding milk of lime or a caustic alkaline solution to a concentrated mother liquor obtained by removing .
(3)母液にホウ酸を添加溶解せしめてある第2項の体
質強化剤。(3) The constitution-strengthening agent according to item 2, in which boric acid is added and dissolved in the mother liquor.
(4)上記水酸化マグネシウムの活性により海水微量成
分を該水酸化マグネシウム中に吸着せしめたものを、更
に海水微量成分を濃縮した母液に入れ、攪拌して、水酸
化マグネシウムに該微量成分を更に吸着せしめてなる第
1項の体質強化剤6本発明で使用するカン水は、前述の
とおりの大酒式塩田で得られるものと、イオン交換法に
よるものとがある。イオン交換法によるカン水は、海水
をイオン交換樹脂膜処理して得られる食塩分の多い濃厚
液である。(4) The above-mentioned magnesium hydroxide has adsorbed trace components of seawater into the magnesium hydroxide, which is further added to a mother liquor containing concentrated trace components of seawater, and stirred to further absorb the trace components into the magnesium hydroxide. Physical Strengthening Agent 6 of Item 1 Made by Adsorption The Kansui used in the present invention can be obtained by the above-mentioned Tashu-style salt pan or by the ion exchange method. Kansui produced by the ion-exchange method is a concentrated liquid with a high salt content obtained by treating seawater with an ion-exchange resin membrane.
この濃厚液を蒸発装置に通してさらに濃縮するとNaC
f、Ca5O,が晶析し、これらの結晶を除去した残り
の液が海水tj&量成分成分濃縮母液るいは単に濃縮母
液と称する。)である。When this concentrated liquid is passed through an evaporator and further concentrated, NaC
f, Ca5O, are crystallized, and the remaining liquid after removing these crystals is called seawater tj & quantity component concentrated mother liquor or simply concentrated mother liquor. ).
本発明により大酒塩田で作業したと全く同じ作用効果を
人体内に持ち込むことが出来るのであるが、本物質がガ
ンに有効であることについての究明は多種類の微量成分
が含有されているのでそれらの相互作用関係をも含めて
極めて困難である。With the present invention, it is possible to bring into the human body exactly the same effects as those obtained by working in Taizake salt fields, but the investigation into the effectiveness of this substance against cancer has not been made because it contains many types of trace ingredients. This is extremely difficult, including the interaction between them.
しかし前述の如く長年にわたっての大酒塩田における実
績がガンに有効であることを立証している。However, as mentioned above, many years of experience in drinking salt fields has proven that it is effective against cancer.
即ち本発明物質の効果に関しては、A表に示す如くガン
予防に対し広大な大酒塩田を使用して、多年にわたり多
人数が参加しての臨床実験的データーが大規模に出され
たものと見做されるので、これを本物質のガンに対する
本質強化剤としての臨床実験データーとすることは十二
分に根拠のあるものと考えられる。In other words, regarding the effects of the substances of the present invention, as shown in Table A, large-scale clinical experimental data has been produced using large-scale sake salt fields and with large numbers of participants over many years. Therefore, it is considered that there is ample basis for using this as clinical experiment data for this substance as an essential cancer-fighting agent.
海水中の微量成分を水酸化マグネシウムに適量含有せし
めてガンを予防する試みは未知のことで本発明の特徴と
する所である。水酸化マグネシウムが人体に制酸緩下剤
として役立つことや副作用を全く伴わないことは公知で
ある。Attempts to prevent cancer by incorporating an appropriate amount of trace components in seawater into magnesium hydroxide are unknown and are a feature of the present invention. It is well known that magnesium hydroxide serves as an antacid laxative for the human body and has no side effects.
本発明は、海水関係から何かガンに対して体質強化出来
るものはないかと多年大規模に探究した結果遂に本物質
に至ったもので、ガンに対する体質強化剤としては全く
未知のものである。The present invention is the result of many years of large-scale research to find something that can strengthen the body against cancer based on seawater, and this substance is completely unknown as an agent for strengthening the body against cancer.
本発明物質はガンに対する強化剤であるが、効果の証明
と容易にするため例をガン発生の恐れのある部分にとっ
て見るに、水酸化マグネシウムに吸着された弱い自然放
射性核種物賞を伴うホウ素物質が上記の部位に集中しガ
ン発生を予防するが、又水酸化マグ冬シウムは制酸緩下
作用及び体内発生の有害ガスを吸収無害化し、ミネラル
物質は正常な生体活動に役立つ等の相乗的効果と相まっ
てガン発生を抑制するものと考える。この効果は前述の
大酒塩田で常時従事している場合におけるガン予防の機
構作用と全く同様である。前述の作用効果を推察する一
根拠を示せばホウ素が放射性物質からの放射能を吸収す
ることや体内においてガン等の腫瘍物のある患部にホウ
素が集中されること等はすでに究明されている所である
。The substance of the present invention is a strengthening agent against cancer, but in order to easily prove its effectiveness, we will take an example of a part that is likely to cause cancer.A boron substance with a weak natural radionuclide adsorbed on magnesium hydroxide is concentrated in the above-mentioned areas and prevents the development of cancer, while magwincinium hydroxide has an antacid-laxative effect and absorbs and renders harmful gases generated in the body harmless, and mineral substances have synergistic effects such as contributing to normal biological activities. Combined with its effectiveness, it is thought to suppress the occurrence of cancer. This effect is exactly the same as the above-mentioned mechanism of cancer prevention when people are constantly engaged in drinking salt fields. One basis for inferring the above-mentioned effects is that it has already been determined that boron absorbs radioactivity from radioactive substances and that boron is concentrated in areas of the body that have tumors such as cancer. It is.
又、1976年第60回米国実験生物学会において、ク
リスチン・ウィルソン女史と、ニコラス・ベトラキス氏
の共同研究でSe(セレン)含有の比較的多い食物を採
ることにより乳ガンに罹る率が少ないとの報告や197
6年日本栄養食料学会においては海藻中に含まれている
I(ヨード)が発ガン性を抑える事実が報告されている
。Also, in 1976, at the 60th Annual Meeting of the American Society for Experimental Biology, a joint study by Ms. Christine Wilson and Mr. Nicholas Betrakis reported that eating foods relatively high in Se (selenium) reduces the chance of developing breast cancer. Ya197
At the 2006 Japanese Society of Nutrition and Food Science, it was reported that I (iodine) contained in seaweed suppresses carcinogenicity.
以下に本発明の体質強化剤′!#遺のための実施例を列
挙する。しかし、本発明は下記例に限定されるものでは
ない。Below are the constitution strengthening agents of the present invention! # List examples for legacy. However, the present invention is not limited to the following examples.
例」−
原料海水としては有害な水銀重金属、PCB、農薬、油
類等の人体有害物質を除去した清澄なる海水と使用した
。Example - Clear seawater from which harmful substances such as mercury heavy metals, PCBs, pesticides, and oils have been removed was used as raw material seawater.
一般に公知の濾過を行なって、清澄海水を得、これをイ
オン交換樹脂膜処理を行なう事によりNaC1分の濃縮
したカン水が得られる。Generally known filtration is performed to obtain clear seawater, which is then treated with an ion exchange resin membrane to obtain kansui with a concentration of 1 NaC.
次にこれを蒸発装置に通す事により、MgCl2濃度を
海水の30〜50倍に濃縮するとNaC1,CaSO3
が晶析する。Next, by passing this through an evaporator, the MgCl2 concentration is concentrated to 30 to 50 times that of seawater, resulting in NaCl and CaSO3.
crystallizes.
これら(NaC1,Ca5O<)を除去した後の母液を
(以下濃縮母液と称する。)を使用した。The mother liquor after removing these (NaCl, Ca5O<) (hereinafter referred to as concentrated mother liquor) was used.
この母液は前記のごとく大酒塩田での母液とほぼ同様の
濃度及び成分組成にある。As mentioned above, this mother liquor has almost the same concentration and composition as the mother liquor from Taizake Salt Farm.
尚イオン交換樹脂膜の性質により処理後の海水中のマグ
ネシウム量対ホウ素量の割合において海水の比率より著
しく少ない場合がある。この場合はホウ酸の如きホウ素
を添加して海水における場合と略同様の割合にして自然
界の状態に保持する。Depending on the properties of the ion exchange resin membrane, the ratio of magnesium to boron in seawater after treatment may be significantly lower than the ratio of seawater. In this case, boron such as boric acid is added to maintain the natural state in substantially the same proportion as in seawater.
以上の様にして得られた濃縮母液4801(11半にM
g、52g、B 、0.078g、K 、35.、Ca
、21f含有)と、生石灰59.5Ag(純度98%)
に水2651を加えた石灰乳とと徐々に性態攪拌する。Concentrated mother liquor 4801 (11 and a half M
g, 52g, B, 0.078g, K, 35. , Ca
, 21f) and quicklime 59.5Ag (98% purity)
and lime milk to which water 2651 has been added.
ここで得られた水酸化マグネシウムと塩化カルシウムと
の懸濁液のうちの1404!(M g(OH)215.
2Ay、CaCL29A9)を反応槽内に残存させ、こ
れを撹拌しながら、これに濃縮母14801(11半に
M g、52y、 B 、0.078g、K 、35g
、Cm、21y含有)と、生石灰59.5Ag(純度9
8%)に水2651を加えた石灰乳とを徐々に性態攪拌
する。1404 of the suspension of magnesium hydroxide and calcium chloride obtained here! (Mg(OH)215.
2Ay, CaCL29A9) remained in the reaction tank, and while stirring, concentrated mother 14801 (11 and a half Mg, 52y, B, 0.078g, K, 35g
, Cm, 21y) and quicklime 59.5Ag (purity 9
8%) and lime milk with water 2651 added to it. Gradually stir the mixture.
このように操作する事により生成した水酸化マグネシウ
ムに微・量成分が効率よく吸着される。By operating in this manner, trace and minor components are efficiently adsorbed to the magnesium hydroxide produced.
注入f115分間攪拌した後フィルタープレスにかけ、
40分にして母液たる塩化カルシウム溶液と水酸化マグ
ネシウムとに分離する。Injection f1 After stirring for 15 minutes, apply to a filter press,
After 40 minutes, the solution is separated into a calcium chloride solution as a mother liquor and magnesium hydroxide.
次にフィルタープレスに水を送り、2時間して水酸化マ
グネシウムの水洗を完了し、ケーキとして水酸化マグネ
シウム123Ag(M g(OH)z49%、H2O4
7%その他4%)を得た。Next, water was sent to the filter press, and after 2 hours, water washing of magnesium hydroxide was completed, and magnesium hydroxide 123Ag (M g (OH) z 49%, H2O4
7%, other 4%).
この水酸化マグネシウム沈澱物を水洗、約80℃熱風乾
燥する。(余り高熱で乾燥するとV&量酸成分含有する
水酸化マグネシウムに変化がおこるので自然の態型を保
つためできるだけ低温乾燥する。)かくして海水中の微
量成分を適量含有せしめた活性水酸化マグネシウムが得
られる0本発明における木質強化剤はこの物質である。This magnesium hydroxide precipitate is washed with water and dried with hot air at about 80°C. (Drying at too high a temperature will cause changes in the magnesium hydroxide containing the V&acid components, so dry at as low a temperature as possible to maintain its natural form.) In this way, active magnesium hydroxide containing an appropriate amount of trace components found in seawater is obtained. The wood reinforcing agent in the present invention is this substance.
しかしこの物質を乾燥加工して得た酸化マグネシウムも
当然本発明に含まれる。However, magnesium oxide obtained by dry processing this substance is also naturally included in the present invention.
かくして得た製品は1グラム中にM g (OH) 2
980置2、B2032m1F、coz5mg、K2O
2&1F、Sr0.3HS Rb0.018mg、Th
O,0OO03zy、Ra I X 1O−1ozy、
UO,OOlmyの自然放射性核種群やCa、Al、S
i、Na。The product thus obtained contains M g (OH) 2 in 1 gram.
980 2, B2032m1F, coz5mg, K2O
2&1F, Sr0.3HS Rb0.018mg, Th
O,0OO03zy, Ra I X 1O-1ozy,
Natural radionuclides of UO, OOlmy, Ca, Al, S
i, Na.
S、Fe等の酸化物水酸化物、塩類並びに微量の重金属
酸化物が多種類吸着して含有されている。A wide variety of oxide hydroxides, salts, and trace amounts of heavy metal oxides such as S and Fe are adsorbed and contained.
しかし分析困難であるが、吸着含有が推定されるより微
量な物質をも含めた詳細表を作成すれば0表の通りであ
る。However, although it is difficult to analyze, if a detailed table including even trace amounts of substances that are estimated to be adsorbed, it would be as shown in Table 0.
眸1
前回の操作で生成された水酸化マグネシウムの懸濁する
塩化カルシウム溶液を反応槽内に残存させない点以外は
例1と同様にして、水酸化マグネシウムを製造しな、得
られた水酸化マグネシウム1g中にはM g(OH)2
980肩g含有されていた。Picture 1 Magnesium hydroxide was produced in the same manner as in Example 1, except that the calcium chloride solution in which magnesium hydroxide was suspended, which was produced in the previous operation, was not left in the reaction tank. 1g contains Mg(OH)2
It contained 980 grams.
λ工
例1にて得られる清澄海水(Mg0.14%含有)1k
lに濃縮工程を経ることなく直接lO%石灰乳30kg
(使用石灰純度98%)を添加し、添加後約1時間攪拌
した後約20時間静置した。1k of clear seawater (containing 0.14% Mg) obtained in λ Example 1
30 kg of 10% lime milk directly without going through the concentration process
(Used lime purity 98%) was added, stirred for about 1 hour after the addition, and then left to stand for about 20 hours.
その117過、水洗する事により水酸化マグネシウムケ
ーキを得る方法り外は製造例1と同様にして水酸化マグ
ネシウムを製造した。得られた水酸化マグネシウム1g
中にはMa+(○H)29601g含有されていた。Magnesium hydroxide was produced in the same manner as in Production Example 1, except for the method of obtaining a magnesium hydroxide cake by filtration and washing with water. 1 g of obtained magnesium hydroxide
It contained 29,601 g of Ma+ (○H).
l1
例1にて得られるカン水(Mg0.69%含有)1.1
に濃縮工程を経ることなく直接10%石灰乳140に9
(使用生石灰純度98%〉を添加し、約1時間攪拌した
後約20時間静置した。l1 Kansui obtained in Example 1 (containing 0.69% Mg) 1.1
10% lime milk directly without going through the concentration process to 140 to 9
(Quicklime purity used: 98%) was added, stirred for about 1 hour, and then left to stand for about 20 hours.
そのthe過、水洗する事により水酸化マグネシウムケ
ーキを得る方法以外は製造例1と同様にして水酸化マグ
ネシウムを製造した。得られた水酸化マグネシウム1g
中にはMe(OH)z9701y含有されていた。Magnesium hydroxide was produced in the same manner as in Production Example 1 except for obtaining a magnesium hydroxide cake by filtering and washing with water. 1 g of obtained magnesium hydroxide
It contained Me(OH)z9701y.
以上の方法にて製造された微量成分を含有する水酸化マ
グネシウムに下記組成で医薬用各種添加剤を加えて混合
、加圧、成型して打錠を行ない、錠剤として服用に供す
ることができる。Magnesium hydroxide containing trace components produced by the above method is mixed with various pharmaceutical additives in the following composition, mixed, pressed, and molded to form a tablet, which can then be taken as a tablet.
水酸化マグネシウム錠処方(1錠当り)水酸化マグネシ
ウム 320.OBリン酸水素カルシウ
ム 333デキストリン
13.7結晶セルロース
45.0ヒドロキシプロピルセルロース 22
.5力ルボキシメチルセルロース
カルシラl=<CMC−Ca) 10.5!
−メントール 0.5ステアリ
ン酸マグネシウム 4.5計45019
几i
例1にて生成された水酸化マグネシウムの乾燥前高10
0Ayを濃縮母液LAN中に入れ、緩和に1時間攪拌し
て、微量成分を再度吸着させた。Magnesium hydroxide tablet formulation (per tablet) Magnesium hydroxide 320. OB calcium hydrogen phosphate 333 dextrin
13.7 Crystalline cellulose
45.0 Hydroxypropyl cellulose 22
.. 5-force carboxymethylcellulose calcilla=<CMC-Ca) 10.5!
- Menthol 0.5 Magnesium stearate 4.5 Total 45019 几i Height before drying of magnesium hydroxide produced in Example 1 10
0Ay was placed in the concentrated mother liquor LAN and gently stirred for 1 hour to adsorb trace components again.
その後、濾過、水洗する事により、水酸化マグネシウム
ゲーキを得る方法以外は例1と同様にして、水酸化マグ
ネシウムを製造した。得られた水酸化マグネシウム1g
中にはMg(OH)2980tyが含有されていた。Thereafter, magnesium hydroxide was produced in the same manner as in Example 1 except for obtaining magnesium hydroxide cake by filtration and washing with water. 1 g of obtained magnesium hydroxide
It contained 2980 ty of Mg(OH).
本発明に依る物質を1日当り11000t程度体質に応
じ加減して適量の水と共に服用すると、ガン予防に適し
た体質強化の目的を達成できる0服用後は体外に排出さ
れるので、−皮層用したらその後服用せずとも大丈夫と
いうものでないことは、前述の大酒塩田における従業員
の従業中及び退職後のat康追跡調査実績を示すAない
しA3表からしても判断される。したがって常日頃適当
に服用することが必要である。If you take the substance according to the present invention with an appropriate amount of water, adjusting the amount according to your constitution, you can achieve the purpose of strengthening your constitution suitable for cancer prevention.After taking the substance, it will be excreted from the body. The fact that it is not okay to not take the drug after that is also judged from Tables A to A3, which show the results of the AT health follow-up survey of employees at Taizake Shioda during their employment and after their retirement. Therefore, it is necessary to take it appropriately on a daily basis.
O本調査2015名について8!康追跡調査に於いては
現役中は全員ガンに罹患した人がないことが確1zされ
ている。8 about the 2015 people in this survey! Health follow-up surveys have confirmed that none of the soldiers contracted cancer while on active duty.
◎ 本調査での退WA後の罹ガン率は10万人に対し5
0名となる。◎ In this study, the cancer incidence rate after quitting WA was 5 per 100,000 people.
There will be 0 people.
O本調査での昭和18年男子平均32.9才、女子平均
41.0才総平均33.6オ、昭和29年時男子平均3
6.2才、女子平均41.0才で総平均38.1才であ
る。In this survey, the average age for boys in 1945 was 32.9 years old, the average for girls was 41.0 years old, the total average was 33.6 years old, and the average age for boys in 1954 was 3.
The average age for girls is 6.2 years old, 41.0 years old, and the overall average age is 38.1 years old.
O本調査における調査対象者数は2015名である。The number of people surveyed in this study was 2,015.
(本調査未確認者は転居転地等の不明者)◎ ()はガ
ン(新生物)による死亡者を表わす。(Individuals who have not been confirmed in this survey are those whose location is unknown, etc.) ◎ () indicates deaths due to cancer (neoplasm).
O本調査における戦死等の死亡者は含まない。O This survey does not include those killed in battle.
◎ 本調査対象者はM6年より316年の誕生者が対象
である。◎ The subjects of this survey are those born between the years M6 and 316.
◎ 本調査において勤務中の死亡者は病没者15名中に
はガンの死亡者はない。◎ Among the 15 people who died due to illness during work in this survey, there were no deaths due to cancer.
A2表
A3表
上記A表に示した調査結果の分析と本発明の体質強化剤
の有効性(発癌抑止効果)を関連付けるための薬理実験
をラットを使用して次のように行なった。Table A2 Table A3 Pharmacological experiments were conducted using rats as follows to correlate the analysis of the survey results shown in Table A above with the effectiveness (carcinogenicity inhibiting effect) of the constitution-enhancing agent of the present invention.
万−1−
6週令の雄F344ラット155匹を用い、6群に分け
た。第1群(32匹)には25%g/kg体重のメチル
アゾキシメタノール(M A M )アセテート〔シグ
マケミカル社、アメリカ、セントルイス(SigsaC
he曽。A total of 155 male F344 rats, 6 weeks old, were used and divided into 6 groups. The first group (32 animals) was treated with 25% g/kg body weight of methylazoxymethanol (MAM) acetate [Sigma Chemical Co., St. Louis, USA (SigsaC
He so.
Co、Ltd、、St、Louis、U、S 、A、)
製〕を週1回計3回腹腔内投与した。動物には基礎食C
E−2〔フレア ジャパン(CLEA Japan、
Co、LLd、。Co, Ltd,, St, Louis, U, S, A,)
] was administered intraperitoneally once a week for a total of three times. Basal food C for animals
E-2 [CLEA Japan,
Co, LLd,.
東京)製〕を実験期間中投与した。第2群(31匹)に
はMAMアセテートを第1群と同様に投与し、発癌剤投
与終了後2週より、実施例1で得られた本発明の体質強
化剤を0.05%含む飼料を、実験終了時まで投与した
。第3群(32匹)はMAMアセテート投与後、上記体
質強化剤0.1%含有飼料を第2群と同様に投与した。(manufactured by Tokyo)] was administered during the experimental period. MAM acetate was administered to the second group (31 animals) in the same manner as in the first group, and from 2 weeks after the end of administration of the carcinogenic agent, feed containing 0.05% of the constitution strengthening agent of the present invention obtained in Example 1 was given. was administered until the end of the experiment. In the third group (32 animals), after administering MAM acetate, the feed containing 0.1% of the constitution strengthening agent was administered in the same manner as in the second group.
第4群(20匹)は上記体質強化剤0.05%含有飼料
のみを、第5群(20匹)には上記体質強化剤0.1%
含有飼料のみを投与した。The 4th group (20 animals) received only feed containing 0.05% of the above constitution strengthener, and the 5th group (20 animals) received 0.1% of the above constitution strengthener.
Only the included feed was administered.
第6群(20匹)には無処置対照群としては基礎食〇E
−2のみを投与した。この実験プロトコールは第1図に
示した。飲用水として水道水を実験期間中投与した。Group 6 (20 animals) received basal diet 〇E as an untreated control group.
-2 only was administered. The experimental protocol is shown in FIG. Tap water was administered as drinking water during the experiment.
実験は255日で終了し屠殺剖検し、剖検時、体重、肝
重量、%肝重量(計重量÷体重x 100)を測定した
。また、全ての臓器、特に大腸、小腸、胃、肝、腎の肉
眼的観察を注意深く行い、10%ホルマリン固定後、常
法で組織切片を作製、H−E染色を行った。腸管腫瘍の
組織学的診断はワード(Ward)、ラボラトリ−・イ
ンベスチゲーシコン(Lab、 I nvest)30
:505−513.<974)及びマスケンス(Mas
kens)とデュジャルデン(D Bardin) 、
Oア(Loies)、キャンサー(Cancer)4
7+81−89.1981の方法に従い、また腎II瘍
はハード(Hard)とパトラ−(13utler)の
キャンサー・リサーチ(CancerRes)30 :
2796−2805 、1970の診断基準に従って診
断した。The experiment was completed after 255 days, and the animals were sacrificed and autopsied. At the time of autopsy, body weight, liver weight, and % liver weight (total weight ÷ body weight x 100) were measured. In addition, all organs, especially the large intestine, small intestine, stomach, liver, and kidney, were carefully observed macroscopically, and after fixation with 10% formalin, tissue sections were prepared using a conventional method and stained with H-E. Histological diagnosis of intestinal tumors is performed by Ward (Lab, Invest) 30.
:505-513. <974) and Maskens (Mas
Kens) and D Bardin,
Loies, Cancer 4
7+81-89.1981, and renal II tumors were treated according to the method of Hard and 13utler, CancerRes 30:
The diagnosis was made according to the diagnostic criteria of 2796-2805, 1970.
統計学的有意差の検定はスチューデントのし一検定(S
tudent’ s t−test)、×2検定、フ
ィッシャー (F isl+er)の直接確率計算法に
て行ない、P=0.05以下を有意差とした。Statistically significant differences were tested using Student's Shiichi test (S
(student's t-test), ×2 test, and Fisher's exact probability calculation method, and P=0.05 or less was considered a significant difference.
l
第2群の実験開始後126日で死亡したラットの大腸、
腎に腫瘍が認められたため、126日以上生存した動物
を有効動物とした。実験終了時の各群における有効動物
数、平均生存日数、体重、肝重量、%肝重量、第2,3
群の平均体重は第1群に比し有窓に低下していた以外は
各群間に有意差を認めなかった。l Large intestines of rats that died 126 days after the start of the experiment in the second group;
Because tumors were found in the kidneys, animals that survived for 126 days or more were considered effective animals. Effective number of animals in each group at the end of the experiment, average survival days, body weight, liver weight, % liver weight, second and third
No significant difference was observed between the groups, except that the average body weight of each group was significantly lower than that of the first group.
各群における腫瘍の発生頻度を表1に示すが、第1.2
.3群のみに腫瘍発生が認められた腫瘍は主として大腸
に発生し、低頻度ながら小腸、腎にも認められた。The frequency of tumor occurrence in each group is shown in Table 1.
.. Tumors, which were observed to occur only in Group 3, mainly occurred in the large intestine, and were also found in the small intestine and kidneys, although less frequently.
腫瘍発生頻度では第2.3群ともに大腸腫瘍発生頻度が
第1群に比し低く、第2群と第1群間に統計学的有意差
を認めた(腺腫+腺癌:P <0.0002;1111
11 : P <0.003;腺癌:P<0.003)
。小腸腫瘍の発生頻度には第1と第2,38¥間に有意
差を認めなかった、大腸と小腸を合わせた全腸管腫瘍の
発生頻度では第2.3群いずれも第1群に比し低値を示
し、第2群と第1群間には統計学的有意差がみられた(
腺腫+腺癌:P<0.001;腺11:P<0.003
;腺癌:P<0.008)。Regarding the frequency of tumor occurrence, the frequency of colon tumor occurrence was lower in both groups 2 and 3 than in group 1, and a statistically significant difference was observed between group 2 and group 1 (adenoma + adenocarcinoma: P <0. 0002;1111
11: P <0.003; Adenocarcinoma: P < 0.003)
. There was no significant difference in the incidence of small intestine tumors between groups 1, 2, and 38 yen.In terms of the incidence of tumors in the entire intestinal tract (large intestine and small intestine combined), both groups 2 and 3 were higher than group 1. It showed a low value, and there was a statistically significant difference between the second group and the first group (
Adenoma+adenocarcinoma: P<0.001; Gland 11: P<0.003
; adenocarcinoma: P<0.008).
腎腫瘍は組織学的には開業系腫瘍であり、大腸、小腸腫
瘍を合わせた全腫瘍の発生頻度でも第2゜3群いずれも
第1群に比し低く、第2群、第1群間に統計学的有意差
が認められた(P<0.005)。Kidney tumors are histologically treated as tumors in private practice, and the incidence of all tumors, including large intestine and small intestine tumors, is lower in both Groups 2 and 3 than in Group 1; A statistically significant difference was observed (P<0.005).
各群間における発生腫瘍の組織型の差はみられず、また
大腸腫瘍の発生部位の差も認められなかった。There were no differences in the histological type of tumors between the groups, nor were there any differences in the location of colon tumors.
上記体質強化剤含有飼料投与によりMAMアセテート誘
発大腸腫瘍の発生頻度は有意に低下した。The frequency of occurrence of MAM acetate-induced colon tumors was significantly reduced by administration of the diet containing the constitution strengthening agent.
特に、005%濃度の飼料はその抑制効果が顕著であっ
た。In particular, the suppressive effect of the feed with a concentration of 0.005% was remarkable.
第1図は本発明の体質強化剤の有効性を説明する薬理実
験のプロトコールを示す概略図で、図中の印は次のよう
な意味を有する:
↓ : MAMアセテート25xg/kg体重体重的
腔内投
与:実施例1で得られた体質強化剤0.1%× : 屠
殺
ニー4Figure 1 is a schematic diagram showing the protocol of a pharmacological experiment to explain the effectiveness of the constitution-strengthening agent of the present invention, and the marks in the figure have the following meanings: ↓: MAM acetate 25xg/kg body weight Internal administration: Constitution strengthening agent obtained in Example 1 0.1% ×: Slaughter knee 4
Claims (4)
成分濃縮物からなるガン予防のための体質強化剤。(1) A constitution strengthening agent for cancer prevention consisting of a seawater trace ingredient concentrate containing magnesium hydroxide as the main ingredient.
塩(NaCl)および硫酸カルシウム(CaSO_4)
を取り除いてなる濃縮した母液に石灰乳または苛性アル
カリ溶液を加えて水酸化マグネシウムを生成せしめたも
のである特許請求の範囲第1項の体質強化剤。(2) Seawater trace component concentrates are salt (NaCl) and calcium sulfate (CaSO_4) from seawater or canned water.
The constitution strengthening agent according to claim 1, wherein magnesium hydroxide is produced by adding milk of lime or a caustic alkaline solution to a concentrated mother liquor obtained by removing the hydroxide.
範囲第2項の体質強化剤。(3) The constitution strengthening agent according to claim 2, wherein boric acid is added and dissolved in the mother liquor.
分を該水酸化マグネシウム中に吸着せしめたものを、更
に海水微量成分を濃縮した母液に入れ、攪拌して、水酸
化マグネシウムに該微量成分を更に吸着せしめてなる特
許請求の範囲第1項の体質強化剤。(4) The above-mentioned magnesium hydroxide has adsorbed trace components of seawater into the magnesium hydroxide, which is further added to a mother liquor containing concentrated trace components of seawater, and stirred to further absorb the trace components into the magnesium hydroxide. The constitution strengthening agent according to claim 1, which is obtained by adsorption.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63133705A JPH01305031A (en) | 1988-05-31 | 1988-05-31 | Constitution-strengthening agent for prevention of cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63133705A JPH01305031A (en) | 1988-05-31 | 1988-05-31 | Constitution-strengthening agent for prevention of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH01305031A true JPH01305031A (en) | 1989-12-08 |
Family
ID=15110965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63133705A Pending JPH01305031A (en) | 1988-05-31 | 1988-05-31 | Constitution-strengthening agent for prevention of cancer |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01305031A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005039601A1 (en) * | 2003-10-27 | 2005-05-06 | Yoshinobu Kozuka | Anticancer drug from deep sea water |
-
1988
- 1988-05-31 JP JP63133705A patent/JPH01305031A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005039601A1 (en) * | 2003-10-27 | 2005-05-06 | Yoshinobu Kozuka | Anticancer drug from deep sea water |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
de la Huerga et al. | Urinary excretion of choline metabolites following choline administration in normals and patients with hepatobiliary diseases | |
Graeme et al. | Heavy metal toxicity, part I: arsenic and mercury | |
EP1838617B1 (en) | Calcium potassium ferrocyanide, a prophylactic mixture comprising this compound and the use thereof for decorporation of radiocesium in subjects affected by nuclear radiation | |
Decker et al. | Adsorption of drugs and poisons by activated charcoal | |
Wills et al. | Water content of aluminum, dialysis dementia, and osteomalacia. | |
Lijinsky et al. | Feeding tests in rats on mixtures of nitrite with secondary and tertiary amines of environmental importance | |
Cullen et al. | Pediatric arsenic ingestion | |
Jenkinson et al. | Effects of noradrenaline and isoprenaline on the permeability of depolarized intestinal smooth muscle to inorganic ions | |
WO1993020826A1 (en) | Pharmaceutical composition | |
Sayre | A Manual of Organic Materia Medica and Pharmacognosy: An Introduction to the Study of the Vegetable Kingdom and the Vegetable and Animal Drugs (with Syllabus of Inorganic Remedial Agents) Comprising the Botanical and Physical Characteristics, Source, Constituents, Pharmacopoeial Preparations, Insects Injurious to Drugs, and Pharmacal Botany | |
Kreppel et al. | Antidotal efficacy of newly synthesized dimercaptosuccinic acid (DMSA) monoesters in experimental arsenic poisoning in mice | |
JPH01305031A (en) | Constitution-strengthening agent for prevention of cancer | |
JP5991543B2 (en) | Anticancer drug | |
Perrin | Medicinal chemistry | |
Saha et al. | Aluminium phosphide poisoning cases in a tertiary care hospital | |
US2673827A (en) | Therapeutic ion exchange resin mixture | |
JPS6356205B2 (en) | ||
Weisman | Studies on the Time Required for the Elimination of Quinidine from the Heart and Other Organs | |
RU2527042C1 (en) | Biologically active food additive for osteoporosis prevention | |
Runhaar et al. | A case of fatal endrin poisoning | |
Lander | Veterinary toxicology | |
Olkkola | Does ethanol modify antidotal efficacy of oral activated charcoal studies in vitro and in experimental animals | |
Bahl | Studies on the Structure, Development, and Physiology of the Nephridia of Oligochaeta PART VIII: Biochemical Estimations of Nutritive and Excretory Substances in the Blood and Coelomic Fluid of the Earthworm and their Bearing on the Role of the Two Fluids in Metabolism | |
Barrie et al. | Calcium disodium edathamil in the treatment of ferrous sulfate poisoning | |
Wynn et al. | THE ALIMENTARY ABSORPTION OF SOME ENTERIC‐COATED SODIUM AND POTASSIUM CHLORIDE TABLETS |